Achaogen Inc (NASDAQ:AKAO) CFO Tobin Schilke sold 2,087 shares of the stock in a transaction on Monday, June 11th. The shares were sold at an average price of $11.95, for a total transaction of $24,939.65. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Shares of Achaogen traded up $0.17, hitting $12.12, during midday trading on Thursday, Marketbeat reports. The company’s stock had a trading volume of 791,945 shares, compared to its average volume of 1,206,465. The company has a current ratio of 7.01, a quick ratio of 7.01 and a debt-to-equity ratio of 0.24. The company has a market cap of $539.79 million, a P/E ratio of -3.82 and a beta of 0.96. Achaogen Inc has a 12-month low of $9.83 and a 12-month high of $25.22.
Achaogen (NASDAQ:AKAO) last posted its quarterly earnings results on Friday, May 4th. The biopharmaceutical company reported ($1.06) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.89) by ($0.17). The business had revenue of $2.14 million during the quarter, compared to analysts’ expectations of $1.25 million. Achaogen had a negative return on equity of 97.86% and a negative net margin of 2,384.08%. analysts expect that Achaogen Inc will post -3.43 earnings per share for the current year.
Several large investors have recently bought and sold shares of AKAO. BlackRock Inc. lifted its stake in shares of Achaogen by 28.6% in the fourth quarter. BlackRock Inc. now owns 2,837,846 shares of the biopharmaceutical company’s stock worth $30,478,000 after buying an additional 630,547 shares in the last quarter. Renaissance Technologies LLC lifted its stake in shares of Achaogen by 3,318.6% in the fourth quarter. Renaissance Technologies LLC now owns 642,700 shares of the biopharmaceutical company’s stock worth $6,903,000 after buying an additional 623,900 shares in the last quarter. Prosight Management LP purchased a new position in shares of Achaogen in the fourth quarter worth about $6,132,000. Deutsche Bank AG lifted its stake in shares of Achaogen by 307.3% in the fourth quarter. Deutsche Bank AG now owns 517,221 shares of the biopharmaceutical company’s stock worth $5,553,000 after buying an additional 390,241 shares in the last quarter. Finally, AXA increased its position in Achaogen by 449.6% during the fourth quarter. AXA now owns 442,921 shares of the biopharmaceutical company’s stock worth $4,757,000 after purchasing an additional 362,337 shares during the last quarter. 68.72% of the stock is currently owned by hedge funds and other institutional investors.
Several research firms have issued reports on AKAO. BidaskClub raised shares of Achaogen from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Zacks Investment Research downgraded shares of Achaogen from a “hold” rating to a “sell” rating in a report on Tuesday, May 1st. Mizuho reaffirmed a “buy” rating on shares of Achaogen in a report on Thursday, May 3rd. Needham & Company LLC reaffirmed a “buy” rating and set a $20.00 price objective on shares of Achaogen in a report on Monday, April 30th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $29.00 price objective (up from $19.00) on shares of Achaogen in a report on Monday, April 30th. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Achaogen has a consensus rating of “Buy” and an average target price of $22.67.
Achaogen Company Profile
Achaogen, Inc, a late-stage biopharmaceutical company, focusses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae.
Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.